Pfizer to Acquire FoldRx


Drug company Pfizer (NYSE:PFE) has consented to acquire FoldRx, a pharmaceutical company that manufactures treatments for rare diseases in the U.S. and in the European Union.

The deal is expected to close this year, and Pfizer will pay a large sum up-front for the company, however the exact terms of the deal were not disclosed.

Continue Reading Below

The head of Pfizer's specialty-care business, Geno Germano, announced in a company release that the acquisition of FoldRx would add to the company’s portfolio of “investigational drugs” for rare diseases, and assist the company’s growth in the neuroscience disease arena.

What do you think?

Click the button below to comment on this article.